Can I Take Vitamin D with Prometrium?

The Short Answer: No Dangerous Interaction Exists

Taking vitamin D alongside Prometrium is safe for most women. No pharmacokinetic study has identified a meaningful change in micronized progesterone absorption, distribution, metabolism, or excretion when vitamin D is co-administered. The two compounds act on separate receptor systems, and their bone-related effects are complementary rather than antagonistic.

Why This Question Arises

Women prescribed Prometrium are almost always in a hormone therapy context, typically post-menopausal or peri-menopausal. Vitamin D deficiency affects roughly 41.6% of U.S. Adults, according to a 2011 NHANES analysis published in Nutrition Research (PMID 22170364). Because both estrogen-progesterone therapy and vitamin D influence bone mineral density, patients and clinicians reasonably wonder whether the combination requires special precautions.

What "No Interaction" Actually Means Clinically

"No interaction" does not mean the two substances are unrelated physiologically. It means neither compound significantly alters the blood levels or receptor activity of the other at standard therapeutic doses. A patient on Prometrium 200 mg nightly and vitamin D3 2,000 IU daily does not need to separate doses by hours or adjust either dose because of the other.

How Prometrium Is Metabolized

Understanding the absence of interaction requires a basic look at how Prometrium is processed. Micronized progesterone is absorbed in the small intestine, undergoes first-pass hepatic metabolism, and is primarily cleared through cytochrome P450 enzymes, especially CYP3A4, with minor contributions from CYP1A2 and CYP2C19 (FDA label, NDA 019781).

CYP3A4 and Vitamin D

Vitamin D3 (cholecalciferol) is converted to 25-hydroxyvitamin D in the liver and then to the active form 1,25-dihydroxyvitamin D (calcitriol) in the kidney. This hydroxylation involves CYP2R1, CYP27B1, and CYP24A1, not CYP3A4 (PMID 20427238). At supplemental doses of 1,000 to 4,000 IU daily, vitamin D does not induce or inhibit CYP3A4 to a degree that alters progesterone clearance. This is the pharmacokinetic basis for the absence of interaction.

First-Pass Effect and Peanut Oil Formulation

Prometrium capsules contain peanut oil as a vehicle to improve micronized progesterone solubility. Absorption peaks roughly 3 hours after an oral dose (FDA label). Vitamin D, being fat-soluble, is also best absorbed with a fat-containing meal. Taking both supplements with the same meal may modestly improve vitamin D absorption but does not alter progesterone pharmacokinetics.

How Vitamin D Works and Why It Matters on HRT

Vitamin D is a fat-soluble secosteroid that binds the vitamin D receptor (VDR), a nuclear receptor expressed in over 200 tissue types (PMID 21118827). Its classic role is calcium and phosphorus homeostasis. Its broader roles include modulation of immune function, muscle contractility, and cell differentiation.

Vitamin D and Bone Mineral Density

Post-menopausal women lose bone density at an accelerated rate after estrogen withdrawal. The Women's Health Initiative Calcium and Vitamin D trial (WHI-CaD, N=36,282) found that combined calcium (1,000 mg) and vitamin D (400 IU) supplementation produced a modest but statistically significant improvement in hip bone density of 1.06% (P<0.01) over 7 years (PMID 16481636). The WHI-CaD dose was now considered suboptimal by current standards; the Endocrine Society's 2011 clinical practice guideline recommends 1,500 to 2,000 IU daily for adults at risk of deficiency (PMID 21646368).

Progesterone and Bone: A Separate Pathway

Micronized progesterone acts on progesterone receptors (PR-A and PR-B) expressed in osteoblasts. In vitro data and small cohort studies suggest progesterone may stimulate osteoblast proliferation independently of estrogen (PMID 7706341). The clinical magnitude of this effect in post-menopausal women on standard HRT is modest relative to estrogen's contribution, but it does suggest the two agents support bone through distinct, non-competing mechanisms.

Pharmacodynamic Considerations: Do They Interfere With Each Other's Effects?

No published controlled trial has detected a pharmacodynamic antagonism between vitamin D and micronized progesterone. Their receptor systems are independent: progesterone binds nuclear progesterone receptors, vitamin D binds VDR, and neither ligand cross-reacts with the other's receptor at physiologic concentrations (PMID 21118827).

Calcium, PTH, and Hormonal Interactions

One indirect pharmacodynamic consideration involves parathyroid hormone (PTH). Vitamin D suppresses PTH secretion; low vitamin D leads to secondary hyperparathyroidism, which accelerates bone resorption. Estrogen-progesterone HRT also reduces PTH-driven bone resorption. The two treatments therefore converge on the same downstream outcome (reduced bone loss) through separate upstream mechanisms. This is additive, not interactive in a pharmacological sense.

Vitamin D and Sex Hormone-Binding Globulin

One secondary concern sometimes raised is whether vitamin D alters sex hormone-binding globulin (SHBG), which binds progesterone in plasma. A 2015 randomized controlled trial (N=192) published in Menopause found no significant change in SHBG at 12 months with vitamin D3 2,000 IU daily supplementation (PMID 25486364). Free progesterone levels are therefore unlikely to be meaningfully altered by vitamin D supplementation at standard doses.

Evidence on Vitamin D Status in Women on Hormone Therapy

Women prescribed HRT, including Prometrium, are not uniformly vitamin D replete. A cross-sectional analysis of the SWAN cohort (N=2,956 peri-menopausal women) found that 36% had serum 25-hydroxyvitamin D below 20 ng/mL, meeting the Endocrine Society's threshold for deficiency (PMID 17062755). The SWAN data did not show that hormone therapy itself depleted vitamin D, but the high background rate of deficiency in this population makes routine screening clinically sensible.

Does Estrogen Affect Vitamin D Metabolism?

Estrogen receptors are expressed in the kidneys and can modestly upregulate CYP27B1 (the enzyme converting 25-OH-D to active calcitriol). A systematic review of 18 observational studies concluded that estrogen-containing HRT was associated with slightly higher 25-OH-D concentrations compared to non-HRT users, with a pooled mean difference of approximately 2.3 nmol/L (PMID 28671299). The effect size is small and does not translate to a need for vitamin D dose reduction in women on Prometrium.

Progesterone's Specific Role

Progesterone does not appear to independently alter vitamin D metabolism in published pharmacokinetic literature. The interaction database maintained by the Natural Medicines Comprehensive Database (accessed via the NIH Office of Dietary Supplements) lists no interaction between progesterone and vitamin D (NIH Office of Dietary Supplements, Vitamin D Fact Sheet). This classification aligns with the mechanistic analysis above.

Dosing and Timing Recommendations

No dose separation is required between Prometrium and vitamin D. Both are fat-soluble compounds, and both absorb optimally with food. For practical adherence, patients can take them at the same meal. The table below summarizes a straightforward co-administration protocol.

Standard Adult Vitamin D Dosing Alongside Prometrium

The Endocrine Society guideline (2011) recommends the following vitamin D doses for deficiency prevention in adults (PMID 21646368):

• Age 19 to 50: 1,500 to 2,000 IU/day to consistently raise 25-OH-D above 30 ng/mL
• Age 50 to 70: 1,500 to 2,000 IU/day
• Age over 70: 1,500 to 2,000 IU/day, with some individuals requiring up to 4,000 IU/day
• Tolerable upper intake level (UL): 4,000 IU/day for adults (Institute of Medicine 2011)

Prometrium dosing for endometrial protection is typically 200 mg orally at bedtime for 12 days per 28-day cycle (cyclic regimen) or 100 mg at bedtime continuously (FDA label). Neither schedule affects vitamin D dosing.

When to Take Each

Prometrium is best taken at bedtime with food because progesterone's sedative metabolites (5-alpha and 5-beta pregnane derivatives) cause drowsiness in some patients. Vitamin D3 can be taken at any meal. If taken at the same bedtime snack, absorption of both is adequate. Splitting them to different meals is equally acceptable and neither approach alters efficacy.

Monitoring: What Labs to Check

Women on Prometrium plus vitamin D supplementation do not require more intensive monitoring than women on Prometrium alone, provided they stay within standard vitamin D dosing ranges.

Serum 25-Hydroxyvitamin D

The Endocrine Society defines vitamin D sufficiency as serum 25-OH-D at or above 30 ng/mL (75 nmol/L) and deficiency as below 20 ng/mL (PMID 21646368). Baseline testing before starting supplementation is reasonable. Annual retesting is appropriate for women on maintenance doses of 1,000 to 2,000 IU daily. Retesting at 3 months is warranted when treating deficiency with doses of 4,000 IU or higher.

Serum Calcium

At doses at or below 4,000 IU daily, hypercalcemia from vitamin D supplementation alone is rare in patients without granulomatous disease or primary hyperparathyroidism. Serum calcium does not require routine monitoring at standard supplementation doses unless clinical risk factors are present (PMID 21646368).

Progesterone Levels

Monitoring serum progesterone is not standard practice during Prometrium therapy for endometrial protection. If monitoring is clinically indicated for another reason (e.g., luteal phase support in fertility treatment), vitamin D supplementation does not alter the interpretation of progesterone assay results.

Special Populations

Women With Malabsorption or Bariatric History

Both Prometrium and fat-soluble vitamins depend on normal biliary function and intestinal fat absorption. Women with inflammatory bowel disease, celiac disease, or a history of bariatric surgery may have impaired absorption of both. In these patients, checking both serum progesterone (if clinically relevant) and serum 25-OH-D is warranted. Vitamin D doses may need to be substantially higher (up to 50,000 IU weekly in supervised settings) to achieve adequacy (PMID 21646368).

Women With Chronic Kidney Disease

CKD stages 3b and above impair the renal conversion of 25-OH-D to active calcitriol (1,25-OH-D). These patients may require activated forms of vitamin D (calcitriol or alfacalcidol) rather than standard cholecalciferol. Prometrium metabolism is primarily hepatic, so mild-to-moderate CKD does not significantly alter progesterone clearance. These are parallel considerations; vitamin D formulation should be guided by the treating nephrologist, and Prometrium dosing does not change based on vitamin D choice.

Peanut Allergy

The FDA label for Prometrium carries a contraindication for patients with peanut allergy because the capsule vehicle is peanut oil. This restriction applies regardless of vitamin D supplementation status.

What the Clinician Conversation Should Cover

When a patient on Prometrium asks about adding vitamin D, the clinical discussion is brief because the risk profile is low. Reasonable talking points include:

• Confirming the vitamin D dose is within the 1,000 to 4,000 IU daily range
• Checking a baseline 25-OH-D level if not done in the past 12 months
• Noting that vitamin D supports the bone-protective goals of HRT without interfering with progesterone
• Reassuring the patient that no timing separation is required

The North American Menopause Society (NAMS) 2022 Hormone Therapy Position Statement states: "Adequate calcium and vitamin D intake is recommended for all women, and their importance increases with aging and menopause-related bone loss" (menopause.org, 2022 Position Statement). This guidance applies directly to women on Prometrium-containing regimens.

Supplements to Avoid or Use Cautiously With Prometrium

Vitamin D is not on this list, but some supplements do interact with Prometrium via CYP3A4 and are worth distinguishing:

• St. John's Wort (Hypericum perforatum): A potent CYP3A4 inducer that may reduce progesterone plasma concentrations by up to 40% in women (PMID 15123747). Avoid with Prometrium.
• Black cohosh: No well-characterized PK interaction with progesterone, but combined estrogenic effects with HRT require clinical judgment.
• High-dose melatonin (above 10 mg): Theoretical CYP1A2 interaction; clinical significance is uncertain at typical 0.5 to 5 mg sleep doses.
• Magnesium: Works synergistically with vitamin D on bone metabolism with no known interaction with progesterone.

Vitamin D at standard supplemental doses does not belong in any cautionary category alongside Prometrium.